Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : NRF2 inhibitor R16
Catalog No.: PC-21180Not For Human Use, Lab Use Only.
NRF2 inhibitor R16 is a novel mutated KEAP1 (mKEAP1)-selective NRF2 inhibitor, binds KEAP1-mutated proteins (G333C mKEAP1, Kd=2.7 uM) and restores their interaction with NRF2, leading to proteasome-dependent NRF2 degradation.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
NRF2 inhibitor R16 is a novel mutated KEAP1 (mKEAP1)-selective NRF2 inhibitor, binds KEAP1-mutated proteins (G333C mKEAP1, Kd=2.7 uM) and restores their interaction with NRF2, leading to proteasome-dependent NRF2 degradation.
R16 significantly inhibits G333C, G364C, or R460S KEAP1 mutants with IC50 of <10 uM in ARE-luc reporter assays.
R16 is barely active against BT-20 cells, which bear WT-KEAP1.
R16 directly binds G333C mKEAP1, with a KD of 2.7 ± 0.6 μM, with no significant interaction with WT-KEAP1.
R16 dose-dependently decreases the NRF2 level in A549, H1648, and H322 cells, but not change in transcription level.
R16 dose-dependently decreases the mRNA levels of GCLM and NQO1, which are two well-established NRF2 transcription targets.
R16 dose-dependently decreases NRF2 protein in A549ctl cells bearing the G333C mutant, but not in A549(WT-KEAP1) cells.
R16 at submicromolar concentrations selectively sensitizes KEAP1-mutated cancer cells, but not WT-KEAP1 cells, to cisplatin and gefitinib.
R16 (110 mg/kg, i.p. daily) shows in vivo efficacy and selectively sensitized A549ctl-derived xenograft to cisplatin (2 mg/kg).
| M.Wt | 442.53 | |
| Formula | C22H26N4O4S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Aboulkassim T, et al. Cell Rep. 2023 Sep 12;42(9):113104.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
